Leptomeningeal inflammation in multiple sclerosis: Insights from animal and human studies

Cassie Wicken, James Nguyen, Rahul Karna, Pavan Bhargava

Research output: Contribution to journalReview article

Abstract

The presence of leptomeningeal inflammation (LMI) in MS was first identified in 2004 and multiple subsequent studies have confirmed the presence of immune cell collections in the meninges of a subset of MS patients. Pathologically, LMI can range from disorganized immune cell collections in the meninges of patients with relapsing remitting (RRMS) or primary progressive MS (PPMS) to well-organized ectopic lymphoid follicles in secondary progressive MS (SPMS). The presence of LMI has been linked to worse pathological (increased cortical demyelination and neuroaxonal damage) and clinical (earlier age at onset, more rapid progression, shorter time to death) outcomes. Recent studies have also demonstrated the ability of specific MRI sequences to detect areas of leptomeningeal contrast enhancement (LME) which may correspond pathologically to areas of LMI. We summarize findings from both pathological and radiological studies of LMI in MS. We also provide a brief overview of LMI in animal models of MS (experimental autoimmune encephalomyelitis) and ongoing clinical trials attempting to target LMI. Future research will help clarify the role of LMI in MS disease progression, identify the mechanisms through which LMI may contribute to MS pathology and test new approaches to target LMI.

Original languageEnglish (US)
Pages (from-to)173-182
Number of pages10
JournalMultiple Sclerosis and Related Disorders
Volume26
DOIs
StatePublished - Nov 1 2018

Fingerprint

Multiple Sclerosis
Inflammation
Meninges
Autoimmune Experimental Encephalomyelitis
Demyelinating Diseases
Age of Onset
Disease Progression
Animal Models
Clinical Trials
Pathology

Keywords

  • B cells
  • Leptomeningeal inflammation
  • Progressive MS

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Leptomeningeal inflammation in multiple sclerosis : Insights from animal and human studies. / Wicken, Cassie; Nguyen, James; Karna, Rahul; Bhargava, Pavan.

In: Multiple Sclerosis and Related Disorders, Vol. 26, 01.11.2018, p. 173-182.

Research output: Contribution to journalReview article

@article{0c81c604836848aba490dc552ff39910,
title = "Leptomeningeal inflammation in multiple sclerosis: Insights from animal and human studies",
abstract = "The presence of leptomeningeal inflammation (LMI) in MS was first identified in 2004 and multiple subsequent studies have confirmed the presence of immune cell collections in the meninges of a subset of MS patients. Pathologically, LMI can range from disorganized immune cell collections in the meninges of patients with relapsing remitting (RRMS) or primary progressive MS (PPMS) to well-organized ectopic lymphoid follicles in secondary progressive MS (SPMS). The presence of LMI has been linked to worse pathological (increased cortical demyelination and neuroaxonal damage) and clinical (earlier age at onset, more rapid progression, shorter time to death) outcomes. Recent studies have also demonstrated the ability of specific MRI sequences to detect areas of leptomeningeal contrast enhancement (LME) which may correspond pathologically to areas of LMI. We summarize findings from both pathological and radiological studies of LMI in MS. We also provide a brief overview of LMI in animal models of MS (experimental autoimmune encephalomyelitis) and ongoing clinical trials attempting to target LMI. Future research will help clarify the role of LMI in MS disease progression, identify the mechanisms through which LMI may contribute to MS pathology and test new approaches to target LMI.",
keywords = "B cells, Leptomeningeal inflammation, Progressive MS",
author = "Cassie Wicken and James Nguyen and Rahul Karna and Pavan Bhargava",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.msard.2018.09.025",
language = "English (US)",
volume = "26",
pages = "173--182",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",

}

TY - JOUR

T1 - Leptomeningeal inflammation in multiple sclerosis

T2 - Insights from animal and human studies

AU - Wicken, Cassie

AU - Nguyen, James

AU - Karna, Rahul

AU - Bhargava, Pavan

PY - 2018/11/1

Y1 - 2018/11/1

N2 - The presence of leptomeningeal inflammation (LMI) in MS was first identified in 2004 and multiple subsequent studies have confirmed the presence of immune cell collections in the meninges of a subset of MS patients. Pathologically, LMI can range from disorganized immune cell collections in the meninges of patients with relapsing remitting (RRMS) or primary progressive MS (PPMS) to well-organized ectopic lymphoid follicles in secondary progressive MS (SPMS). The presence of LMI has been linked to worse pathological (increased cortical demyelination and neuroaxonal damage) and clinical (earlier age at onset, more rapid progression, shorter time to death) outcomes. Recent studies have also demonstrated the ability of specific MRI sequences to detect areas of leptomeningeal contrast enhancement (LME) which may correspond pathologically to areas of LMI. We summarize findings from both pathological and radiological studies of LMI in MS. We also provide a brief overview of LMI in animal models of MS (experimental autoimmune encephalomyelitis) and ongoing clinical trials attempting to target LMI. Future research will help clarify the role of LMI in MS disease progression, identify the mechanisms through which LMI may contribute to MS pathology and test new approaches to target LMI.

AB - The presence of leptomeningeal inflammation (LMI) in MS was first identified in 2004 and multiple subsequent studies have confirmed the presence of immune cell collections in the meninges of a subset of MS patients. Pathologically, LMI can range from disorganized immune cell collections in the meninges of patients with relapsing remitting (RRMS) or primary progressive MS (PPMS) to well-organized ectopic lymphoid follicles in secondary progressive MS (SPMS). The presence of LMI has been linked to worse pathological (increased cortical demyelination and neuroaxonal damage) and clinical (earlier age at onset, more rapid progression, shorter time to death) outcomes. Recent studies have also demonstrated the ability of specific MRI sequences to detect areas of leptomeningeal contrast enhancement (LME) which may correspond pathologically to areas of LMI. We summarize findings from both pathological and radiological studies of LMI in MS. We also provide a brief overview of LMI in animal models of MS (experimental autoimmune encephalomyelitis) and ongoing clinical trials attempting to target LMI. Future research will help clarify the role of LMI in MS disease progression, identify the mechanisms through which LMI may contribute to MS pathology and test new approaches to target LMI.

KW - B cells

KW - Leptomeningeal inflammation

KW - Progressive MS

UR - http://www.scopus.com/inward/record.url?scp=85053826615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053826615&partnerID=8YFLogxK

U2 - 10.1016/j.msard.2018.09.025

DO - 10.1016/j.msard.2018.09.025

M3 - Review article

C2 - 30268038

AN - SCOPUS:85053826615

VL - 26

SP - 173

EP - 182

JO - Multiple Sclerosis and Related Disorders

JF - Multiple Sclerosis and Related Disorders

SN - 2211-0348

ER -